Avapritinib has been approved by the FDA for advanced systemic mastocytosis

August 2021: The FDA approved avapritinib (AyvakitTM, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL).

EXPLORER (NCT02561988) and PATHFINDER (NCT03580655), two multi-center, single-arm, open-label clinical trials recruiting patients with AdvSM, were used to assess efficacy. The overall response rate (ORR) was the primary efficacy outcome measure, as determined by a central committee using modified IWG-MRT-ECNM criteria. Duration of response (DOR), time to response, and changes in individual markers of mast cell burden were also used to assess efficacy. Avapritinib was given to 53 patients in daily doses of up to 200 mg.

In both studies, the overall response rate (ORR) was 57 percent (95 percent CI: 42, 70) (n=53), with 28 percent complete remissions and 28 percent partial remissions. The median response time was 2.1 months and the median response length was 38.3 months (95 percent confidence interval: 19, not estimable).

Edema, diarrhoea, nausea, and fatigue/asthenia were the most prevalent adverse effects in patients taking AdvSM (incidence 20%).

Patients with AdvSM with platelet counts of less than 50 X 109/L should not be treated with avapritinib.

For individuals with AdvSM, the suggested avapritinib dose is 200 mg orally once daily.

Reference: https://www.fda.gov/

Check details here.

Take second opinion on advanced systemic mastocytosis treatment

Send Details

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Gene Therapy for Gaucher’s Disease in China
• Susan Hau

  https://cancerfax.com/author/susan/

  Gene Therapy for Wilson’s Disease in China
• Susan Hau

  https://cancerfax.com/author/susan/

  Gene Therapy for Phenylketonuria in China
• Susan Hau

  https://cancerfax.com/author/susan/

  Best Cancer Hospitals in China 2025